# OnCo record jacobio-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/jacobio-pharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "jacobio-pharmaceuticals" ;
  schema:name "Jacobio Pharmaceuticals"@en ;
  schema:alternateName "Jacobio Pharmaceuticals Co., Ltd."@en, "Jacobio Pharmaceuticals Group Co., Ltd."@en ;
  schema:description "Jacobio Pharmaceuticals is a Beijing cancer-drug developer listed in Hong Kong whose KRAS G12C inhibitor glecirasib was approved in China in 2025 for previously treated lung cancer, and whose pan-KRAS inhibitor JAB-23E73 is licensed to AstraZeneca."@en ;
  schema:url <https://onco.cc/companies/jacobio-pharmaceuticals/>, <https://www.jacobiopharma.com> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.jacobiopharma.com>, <https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0522/2025052200747.pdf>, <https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1221/2025122100421.pdf>, <https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0330/2026033000113.pdf>, <https://clinicaltrials.gov/search?spons=Jacobio%20Pharmaceuticals> ;
  onco:tag "ctgov-sponsor", "china" ;
  schema:addressCountry "CN" ;
  onco:drugs <https://onco.cc/drugs/glecirasib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/allist/> ;
  onco:trials <https://onco.cc/trials/nct06386146/>, <https://onco.cc/trials/nct05490472/>, <https://onco.cc/trials/nct06973564/>, <https://onco.cc/trials/nct04686682/>, <https://onco.cc/trials/nct06959615/>, <https://onco.cc/trials/nct07640295/> .